🔬 AstraZeneca CEO Pascal Soriot called the UK and China "a great match" for science collaboration during this week's UK-China Business Forum in Beijing. With a fresh $15 billion investment plan announced Thursday, the pharma giant aims to turbocharge research and manufacturing in China by 2030.
💡 "China isn't just a market—it's becoming a global innovation engine," said Soriot, praising the country's biopharma talent pool. The move comes as UK Prime Minister Keir Starmer wraps his China visit, signaling renewed cross-border tech partnerships.
📈 The 100-billion-yuan commitment will expand AstraZeneca's Shanghai R&D hub and build new smart factories. Analysts say this could position China as the company's second-largest production base outside Britain.
